TGFB1 and cancer: The need for improved methods to quantitate TGF-β proteins was highlighted recently by a large cancer tissue microarray study showing that TGF-β immunohistochemistry results did not correlate well with TGF-β levels assessed by mRNA quantitation or Western blotting [26], thereby posing challenges for how best to stratify patients for clinical trials with anti-TGF-β therapies.